ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IPS Ipso Ventures

1.425
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ipso Ventures LSE:IPS London Ordinary Share GB00B1GDWB47 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.425 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Ipso Ventures Share Discussion Threads

Showing 1751 to 1765 of 2275 messages
Chat Pages: Latest  79  78  77  76  75  74  73  72  71  70  69  68  Older
DateSubjectAuthorDiscuss
09/11/2011
10:09
Hi everyone, I just bought 56,377 shares @ 3.59p, but showing as a SELL on PLUS market, just so everyone holding here is aware.
moochy
09/11/2011
08:55
Yes Tomboy... it has been a while since any news from the company.

I see the share price is sliding back to the lowly reaches of 3p.....

All this time cash is burning... burning... burning... what will come first, another fund raising exercise or another early sale of one of their technologies... very poor... must try harder....

Then again the management dont exactly have a good pedigree do they... I suppose their other businesses failing does allow them more time to muck this one up.

electrick
09/11/2011
08:39
October 2011 – Buccolam granted first PUMA

Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures

- Approval offers convenient alternative to treat seizures in children and adolescents
- First ever product approved through European Commission's Centralized Paediatric Use Marketing Authorization (PUMA)
Therakind is delighted to announce that the European Commission has granted (September 2011) a Centralized Paediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age. Buccolam is being marketed by Viropharma (www.viropharma.com).

Therakind was responsible for the regulatory development strategy for the product as well as the design, management and sponsoring of the clinical trial. This is the first product approval through the centralized PUMA procedure since its inception.

Buccal midazolam is already being used routinely in the treatment of acute seizures in children both in the UK and Europe but in an unlicensed form. It is now approved throughout all the Member States of the European Union (EU) as well as in the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein.

Buccolam is oromucosal midazolam provided in a pre-filled, age-specific dose formulation for convenient buccal (i.e. via the cavity between the cheek and gum) delivery. Buccal midazolam has been shown in four clinical studies to be either comparable or superior in both its effectiveness and speed of onset of action to the current standard treatment, rectally-administered diazepam, for terminating paediatric convulsive seizures. Epilepsy is among the most common childhood neurological disorders in developed countries, affecting nearly one percent of the population. There are approximately six million people affected by epilepsy in Europe; nearly one million European children and adolescents have active epilepsy. If left untreated, seizures can lead to status epilepticus (SE) and patients may require hospitalization and intensive care.

Therakind sold its controlling interest in Buccolam® in 2010. The Company received a milestone payment on the granting of marketing approval for the product, and will receive royalties on product sales.

For further information, please contact us.

tomboyb
03/11/2011
18:15
Viropharm results - a mention of Buccolam - What management need to address is what royalties are the expecting ( what milestone payment was recieved) - And how is the progress of their pain drug going -

Cambridge Meditech - Formflex range of products with Lantor - Licensing agreement due?

Ipsol Energy - Stake worth £457k -

Medermica - Any news on that - is one of the largest investments? PH sensor / etc

Polyfect - Cheaper plastic technology -

tomboyb
03/11/2011
14:00
thems the traders... watch the spread and how quick it falls back to 3 p this time...

shocking ...

electrick
03/11/2011
11:17
And profit i took, 50k in and out for 0.55p profit per share.
kinghorm23
03/11/2011
09:05
All buys today, plus buyers 35k paying 3.59p
kinghorm23
03/11/2011
08:25
Maybe i should adopt some topinfo/moreforus ramping here now i have just bought
50k ?

"not selling until 20p" "this will hit 10p today"

Will that do, in a nutshell if it has a run i will take a profit simples.

kinghorm23
03/11/2011
07:53
perhaps touch under 3 p today......

traders keep some interest / momentum but it is fading... just like the SP

electrick
02/11/2011
21:50
All the pump and dumpers long gone from here !

moreforus/topinfo/falia/tomboyb

Nowhere to be seen.

Guess it's time to buy when quiet and this lot are not in pump
and dumping it.

kinghorm23
26/10/2011
14:56
well it made the intra day of 2.7p... perhaps this time it will continue the slide... or perhap a painful optimism as it continued to haemorrhage cash whilst receiving nothing back in the door....

COST still higher than Income...
delays in its technologies
major stakerholder left and sold up
company directors with a track record of failed companies
cash calls to prop it up

but i love the optimism here... its why I stick about

electrick
26/10/2011
14:36
i like your thinking Huckle.....
electrick
26/10/2011
14:05
perhaps 3p later today? whaddya think?
electrick
24/10/2011
14:24
life again in the sp
fur
24/10/2011
08:43
shouldnt affect directly unless you consider the directors abilities to manage companies in this difficult market pertinent
electrick
Chat Pages: Latest  79  78  77  76  75  74  73  72  71  70  69  68  Older

Your Recent History

Delayed Upgrade Clock